Sifrol Special Precautions

Renal impairment: When prescribing Sifrol tablets in a patient with renal impairment a reduced dose is suggested in line with Dosage & Administration.
Hallucinations and confusion: Hallucinations and confusion are known side-effects of treatment with dopamine agonists and levodopa in Parkinson's disease patients. Hallucinations were more frequent when Sifrol was given in combination with levodopa in Parkinson's disease patients with advanced disease than in monotherapy in Parkinson's disease patients with early disease. Within the RLS clinical development program for registration, one case of hallucinations has been reported. Patients should be informed that (mostly visual) hallucinations can occur.
Patients should be aware of the fact that hallucinations can occur and may adversely affect their ability to drive.
Abnormal behaviour (reflecting symptoms of impulse control disorders and compulsive behaviours): Patients and caregivers should be made aware of the fact that abnormal behaviour (reflecting symptoms of impulse control disorders and compulsive behaviours) such as binge eating, compulsive shopping, hypersexuality and pathological gambling, have been reported in patients treated with dopaminergic drugs. Dose reduction/tapered discontinuation should be considered.
Patients with psychotic disorders: Patients with psychotic disorders should be treated with dopamine agonists only if the potential benefits outweigh the risks. Co-administration of antipsychotic medicinal products with pramipexole is not recommended, e.g. if dopamine-antagonistic effects can be expected.
Retinal changes in albino rats: Pathologic changes (degeneration and loss of photoreceptor cells) were observed in the retina of albino rats in the 2-years carcinogenicity study. Evaluation of the retinas of albino mice, pigmented rats, monkeys, and minipigs did not reveal similar changes. The potential significance of this effect in humans has not been established, but cannot be disregarded because disruption of a mechanism that is universally present in vertebrates (ie. disk shedding) may be involved.
Postural hypotension: In case of severe cardiovascular disease, care should be taken. It is recommended to monitor blood pressure, especially at the beginning of treatment, due to the general risk of postural hypotension associated with dopaminergic therapy.
Dystonia: Patients with Parkinson's disease may present with axial dystonia such as antecollis, camptocormia or pleurothotonus (Pisa Syndrome). Dystonia has occasionally been reported following initiation of dopamine agonists including pramipexole, although a clear causal relationship has not been established. Dystonia may also occur several months following medication initiation or adjustment. If dystonia occurs, the dopaminergic medication regimen should be reviewed and an adjustment considered.
Sudden onset of sleep and somnolence: Patients should be alerted to the potential sedating effects associated with Sifrol, including somnolence and the possibility of falling asleep while engaged in activities of daily living. Since somnolence is a frequent adverse event with potentially serious consequences, patients should neither drive a car nor operate other complex machinery until they have gained sufficient experience with Sifrol to gauge whether or not it affects their mental and/or motor performance adversely. Patients should be advised that if increased somnolence or episodes of falling asleep during activities of daily living (e.g., conversations, eating, etc.) are experienced at any time during treatment, they should not drive or participate in potentially dangerous activities and should contact their physician.
Melanoma: Epidemiological studies have shown that patients with Parkinson's disease have a higher risk (2- to approximately 6-fold higher) of developing melanoma than the general population. Whether the increased risk observed was due to Parkinson's disease or other factors, such as drugs used to treat Parkinson's disease, is unclear.
For the reasons stated above, patients and providers are advised to monitor for melanoma when using pramipexole or other dopaminergic drugs.
Treatment discontinuation in Parkinson's disease: Symptoms suggestive of a neuroleptic malignant syndrome have been reported with abrupt withdrawal of dopaminergic therapy. (See Dosage & Administration).
Dopamine agonist withdrawal syndrome (DAWS): DAWS has been reported with dopamine agonists, including pramipexole (see Adverse Reactions). To discontinue treatment with patients with Parkinson's disease, pramipexole should be tapered off (see Dosage & Administration). Limited data suggests that patients with impulse control disorders and those receiving high daily dose and/or high cumulative doses of dopamine agonists may be at higher risk for developing DAWS. Withdrawal symptoms may include apathy, anxiety, depression, fatigue, sweating and pain and do not respond to levodopa. Prior to tapering off and discontinuing pramipexole, patients should be informed about potential withdrawal symptoms. Patients should be closely monitored during tapering and discontinuation. In case of severe and/or persistent withdrawal symptoms, temporary readministration of pramipexole at the lowest effective dose may be considered.
Rhabdomyolysis: A single case of rhabdomyolysis occurred in a 49-year-old male with advanced Parkinson's disease treated with Sifrol Tablet. The patient was hospitalized with an elevated CPK (10,631 IU/L). The symptoms resolved with discontinuation of the medication.
Ophthalmologic monitoring: Ophthalmologic monitoring is recommended at regular intervals or if vision abnormalities occurs.
Augmentation in Restless Legs Syndrome: Reports in the literature indicate that treatment of Restless Legs Syndrome with dopaminergic medications can result in augmentation.
Augmentation refers to the earlier onset of symptoms in the evening (or even the afternoon), increase in symptoms, and spread of symptoms to involve other extremities.
Treatment with Sifrol should be started with the recommended dose of 0.125 mg and may only be increased to a maximum recommended daily dose of 0.75 mg, if additional symptom relief is required (see Dosage & Administration). Prior to treatment, patients should be informed that augmentation may occur. They should be regularly monitored for the occurrence of augmentation. If augmentation occurs, the adequacy of pramipexole treatment should be reviewed and dosage adjustment or discontinuation considered.
Effects on ability to drive and use machines: Patients should be aware of the fact that hallucinations can occur and may adversely affect their ability to drive.
Patients should be alerted to the potential sedating effects associated with Sifrol, including somnolence and the possibility of falling asleep while engaged in activities of daily living. (See Warnings & Precautions).